Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Parkinson's Disease
NCT02954978Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Jan 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in Parkinson's disease (PD), Parkinson's disease dementia (PDD), sponsored by Georgetown University. Started Jan 2017; status: completed.
02
Drugs
nilotinib
03
Conditions
Parkinson's disease (PD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT02954978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954978.